Lidocaine hydrochloride is under clinical development by Scilex Holding and currently in Phase II for Low Back Pain. According to GlobalData, Phase II drugs for Low Back Pain have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lidocaine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lidocaine hydrochloride overview

Lidocaine hydrochloride (ZTlido) is an amide type local anesthetic agent. It is formulated as patch for topical application. ZTlido is indicated for the relief of pain associated with post-herpetic neuralgia (PHN), also referred to as post-shingles pain and low back pain.

The drug candidate is applied through trandermal route as a patch. The drug candidate is a next-generation branded lidocaine transdermal patch (1.8%). The drug candidate is a lidocaine transdermal patch (5.4%) for low back pain (SP-103).The drug candidate is developed based on Scilex proprietary patch technology that utilizes a proprietary single-layer anhydrous, drug-in-adhesive, topical delivery system to keep its patches thin and targets local drug delivery. It was under development for the treatment of post-herpetic neuralgia in EU.

Scilex Holding overview

Scilex Holding (Scilex) is a biopharmaceutical company that develop and commercialize non-opioid pain management solutions for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California, the US.

For a complete picture of Lidocaine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.